Clinical trial · Interventional
Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer
Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer
NCT00007930CI-TRIAL-00011872unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Surgery to remove the tumor may be an effective treatment for rectal cancer. It is not yet known whether one type of surgery is more effective than another for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two types of surgery in treating patients who have rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| laparoscopic surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Local recurrence at 3 years
Secondary outcomes (1)
- measure
- Disease-free and overall survival at 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Clinical diagnosis of rectal cancer by colonoscopy or barium enema * Distal margin of tumor arises within 9-15 cm from the anal verge as measured by rigid sigmoidoscopy * No synchronous multiple adenocarcinomas * Candidate for low anterior surgical resection by laparoscopy or conventional open method * No evidence of gross metastatic disease * No evidence of peritoneal or pelvic metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Not specified Life expectancy: * At least 6 months Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No other malignancy within the past 5 years PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Neoadjuvant or adjuvant chemoradiotherapy allowed Endocrine therapy: * Not specified Radiotherapy: * See Chemotherapy Surgery: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.